Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0JB6H
|
|||
Former ID |
DNC004766
|
|||
Drug Name |
6-Methyl-4-morpholin-4-yl-chromen-2-one
|
|||
Synonyms |
CHEMBL361588; 6-methyl-4-morpholin-4-yl-chromen-2-one; 6-Methyl-4-morpholino-coumarin; MolPort-000-485-396; BDBM50159606; ZINC13608106; STK908587; AKOS002216573; MCULE-4100962736; NCGC00327351-01; 6-methyl-4-morpholin-4-ylchromen-2-one; ST096430; AB01322204-02
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C14H15NO3
|
|||
Canonical SMILES |
CC1=CC2=C(C=C1)OC(=O)C=C2N3CCOCC3
|
|||
InChI |
1S/C14H15NO3/c1-10-2-3-13-11(8-10)12(9-14(16)18-13)15-4-6-17-7-5-15/h2-3,8-9H,4-7H2,1H3
|
|||
InChIKey |
XWKCKOOKHALUIU-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA-dependent protein kinase catalytic (PRKDC) | Target Info | Inhibitor | [1] |
KEGG Pathway | Non-homologous end-joining | |||
Cell cycle | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | |||
Coregulation of Androgen receptor activity | ||||
Class I PI3K signaling events mediated by Akt | ||||
BARD1 signaling events | ||||
Reactome | Nonhomologous End-Joining (NHEJ) | |||
WikiPathways | DNA Damage Response | |||
Non-homologous end joining | ||||
FAS pathway and Stress induction of HSP regulation | ||||
Cytosolic sensors of pathogen-associated DNA | ||||
Retinoblastoma (RB) in Cancer | ||||
Prostate Cancer | ||||
Double-Strand Break Repair | ||||
Cell Cycle | ||||
miRNA Regulation of DNA Damage Response |
References | Top | |||
---|---|---|---|---|
REF 1 | Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.